The FDA has issued an emergency use authorization (EUA) for the IV drug Peramivir in children and adults hospitalized with (suspected or confirmed) H1N1. This drug should be used in patients who have not responded (or are not expected to respond) to oral or inhaled anti-viral therapy, or for which the provider determines that IV therapy is appropriate and warranted. Clinicians considering it’s use should read this (Fact Sheet)
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.